AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
暂无分享,去创建一个
Hua Yang | Fang Wang | Zenon Konteatis | Lenny Dang | Wei Liu | P. Opolon | S. Choe | S. Gross | B. Delabarre | Giovanni Cianchetta | Cheng Fang | Wentao Wei | F. Jiang | J. Saunders | Hua Yang | K. Yen | Wei Liu | S. Su | Shengfang Jin | F. Salituro | L. Dang | F. Wang | S. Broutin | A. Paci | O. Bernard | V. Penard-Lacronique | O. Bawa | Lei Jin | M. David | S. de Botton | M. Dorsch | C. Quivoron | B. Marteyn | Z. Konteatis | Byron DeLaBarre | A. Padyana | K. Straley | V. Saada | Lei Jin | L. Silverman | Stefan Gross | Shengfang Jin | Shinsan M. Su | Paule Opolon | Jeremy Travins | Virginie Penard-Lacronique | Kimberly Straley | Erin Artin | Cyril Quivoron | Wentao Wei | Marion Dorsch | Sung Choe | Stéphane de Botton | Olivier A Bernard | Francesco G Salituro | Jeffrey O Saunders | Angelo Paci | Katharine Yen | Muriel D David | Anil Padyana | Erica Tobin | Yue Chen | Raj Nagaraja | Giovanni Cianchetta | Olivia Bawa | Véronique Saada | Sophie Broutin | Benoît S Marteyn | Monika Pilichowska | YingXia Xu | Cheng Fang | Fan Jiang | Lee Silverman | Scott A Biller | Shin-San Michael Su | S. Biller | J. Travins | M. Pilichowska | Erin Artin | E. Tobin | Yue Chen | R. Nagaraja | Yingxia Xu
[1] M. Caligiuri,et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Birnbaum,et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.
[3] R. Verhaak,et al. Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.
[4] Manish R. Patel,et al. Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial , 2015 .
[5] J. Cowland,et al. Granulopoiesis and granules of human neutrophils , 2016, Immunological reviews.
[6] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[7] H. Dombret,et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Jeffrey W. Clark,et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.
[9] N. Pannu,et al. REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.
[10] Wei Liu,et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. , 2014, Blood.
[11] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[12] Narasimhan P. Agaram,et al. Induction of sarcomas by mutant IDH2 , 2013, Genes & development.
[13] C. Thompson,et al. The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.
[14] I. Weissman,et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission , 2014, Proceedings of the National Academy of Sciences.
[15] Fang Wang,et al. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.
[16] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[17] M. Stratton,et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents , 2016, Nature Communications.
[18] S. Broutin,et al. Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[19] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[20] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[21] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[22] Thomas J. Hudson,et al. Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia , 2014, Nature.
[23] G. Reifenberger,et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics , 2012, Nature.
[24] Nicholas D. Adams,et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. , 2015, Nature chemical biology.
[25] Jianping Ding,et al. Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H , 2010, Cell Research.
[26] P. Pandolfi,et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. , 2014, Cell stem cell.
[27] A. Grigoriadis,et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.
[28] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[29] M. Prevost,et al. Anoxia and glucose supplementation preserve neutrophil viability and function. , 2016, Blood.
[30] H. Kantarjian,et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression , 2015, Leukemia.
[31] S. Lowe,et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition , 2013, Genes & development.
[32] W. Kaelin,et al. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. , 2013, Genes & development.
[33] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[34] Zhen-yi Wang,et al. Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.
[35] K. Ross,et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.
[36] M. Konopleva,et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML , 2015, American journal of hematology.
[37] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[38] A. Iafrate,et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.
[39] Benjamin L. Ebert,et al. (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.
[40] A. Viale,et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.
[41] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .
[42] R. Levine,et al. Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia. , 2015, Experimental hematology.
[43] S. Grzesiek,et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.
[44] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[45] D. Campana,et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. , 2011, Journal of the National Cancer Institute.
[46] Tak W. Mak,et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.
[47] R. Klose,et al. The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.
[48] Joseph G Boyer,et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG. , 2011, Biochemistry.
[49] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[50] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[51] R. Hills,et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. , 2011, Blood.